Skip to main content

Miller Steve's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Aug 17, 2021

Accession no.
0001161697-21-000385
Filed
Aug 17, 2021
Trade date
Aug 13, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $249.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Miller SteveCIK 0001402535Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 13, 2021Common stock, par value $0.001 per shareMOption exerciseAcquired+65,000$3.12+$202,800742,687Direct
Aug 13, 2021Common stock, par value $0.001 per shareSSaleDisposed−40,963$6.09F1−$249,464.67701,724Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 13, 2021Common StockAGrant or awardDisposed−65,000$0.00$01,525,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Shares were sold to cover exercise price of options and tax withholding requirements.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)